Prenetics is no longer a leftover diagnostics story. The Cayman issuer spent two years stripping ACT Genomics, Europa, and Insighta so a single powder brand, IM8, could become the entire equity. That brand did not exist twenty months ago. In the quarter ended in June 2026, it produced almost all of group revenue and carried Prenetics through a sixth consecutive record. The investment debate is whether a celebrity-backed subscription powder can keep compounding after the first cash-flow month, or whether the print is an annualization trick dressed as a franchise.
The tension sits between thick contribution profit and a still-lossy reported P&L. Gross margin sat near sixty five percent as manufacturing and freight scaled. Contribution profit reached about $21 million. Adjusted earnings still lost about $19 million because acquisition spend doubled. July flipped consolidated adjusted free cash flow positive, but that metric adds General Catalyst fundings back to operating cash. The market is being asked to treat a financed marketing line as if the factory already pays for itself.
Management raised full-year revenue guidance to a band of $220 million to $230 million. It also opened a next-year IM8 target of $400 million or more, with new SKUs excluded. Shares closed near $24 in mid-September. That price implies about $405 million of equity value. Cash and current financial assets were about $109 million at the print, with almost no bank debt. The next two prints resolve whether sequential IM8 growth stays inside the guided third-quarter band while the cash-flow month becomes a cash-flow quarter.